Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
06 Mars 2018 - 10:05PM
Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that
Bill Lis, chief executive officer, will present at the following
conferences in March:
- Cowen and Company’s 38th Annual Health Care Conference on
Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.
- Oppenheimer’s 28th Annual Healthcare Conference on Tuesday,
March 20, 2018, at 10:55 a.m. Eastern Time in New York.
Both presentations will be webcast live and
available for replay from Portola's website at www.portola.com in
the Investor Relations section.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s first medicine Bevyxxa® (betrixaban), an oral,
once-daily Factor Xa inhibitor, was approved by the U.S. Food
and Drug Administration in June 2017. The company is also
working to advance two clinical programs for andexanet alfa, a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and
follow the Company on Twitter @Portola_Pharma.
Investor Contact: Cara MillerPortola
Pharmaceuticalsir@portola.com
Media Contact:Laurie MasonsonW2O
Grouplmasonson@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur